Cargando…

Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction: A report from the DIGAMI 2 trial

OBJECTIVE: The activation of the complement system may be involved in the pathology of myocardial infarction (MI) and type 2 diabetes. To explore their potential as prognostic markers, we characterized two factors in the complement cascade, the end product sC5b-9 and the mannose-binding lectin–assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mellbin, Linda G., Bjerre, Mette, Thiel, Steffen, Hansen, Troels K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308270/ https://www.ncbi.nlm.nih.gov/pubmed/22357179 http://dx.doi.org/10.2337/dc11-1642

Ejemplares similares

Copeptin, IGFBP-1, and Cardiovascular Prognosis in Patients With Type 2 Diabetes and Acute Myocardial Infarction: A report from the DIGAMI 2 trial
por: Mellbin, Linda G., et al.
Publicado: (2010)

Mannose-Binding Lectin Genotype and Phenotype in Patients With Type 2 Diabetes and Myocardial Infarction: A report from the DIGAMI 2 trial
por: Mellbin, L.G., et al.
Publicado: (2010)

Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans
por: Halkjær, Lene, et al.
Publicado: (2020)

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort
por: Meziani, Sara, et al.
Publicado: (2022)

Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction
por: Wang, Anne, et al.
Publicado: (2021)

Global Autorecognition and Activation of Complement by Mannan-Binding Lectin in a Mouse Model of Type 1 Diabetes
por: Axelgaard, Esben, et al.
Publicado: (2017)

Mannan-Binding Lectin in Diabetic Kidney Disease: The Impact of Mouse Genetics in a Type 1 Diabetes Model
por: Østergaard, Jakob Appel, et al.
Publicado: (2012)

Increased Autoreactivity of the Complement-Activating Molecule Mannan-Binding Lectin in a Type 1 Diabetes Model
por: Østergaard, Jakob Appel, et al.
Publicado: (2016)

Clinical implications of cardiovascular outcome trials in type 2 diabetes
por: Mellbin, L. G., et al.
Publicado: (2019)

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein
por: Yatime, Laure, et al.
Publicado: (2018)

The impact of type 2 diabetes mellitus on prognosis in patients with non-ST elevation myocardial infarction
por: Birkner, Katarzyna, et al.
Publicado: (2017)

Type 2 myocardial infarction in general medical wards: Clinical features, treatment, and prognosis in comparison with type 1 myocardial infarction
por: Furie, Nadav, et al.
Publicado: (2019)

The Impact of Type 2 Diabetes Mellitus on Long-Term Prognosis in Patients of Different Ages with Myocardial Infarction
por: Afanasiev, S. A., et al.
Publicado: (2018)

Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis
por: White, Kyle, et al.
Publicado: (2022)

Corrigendum to “The Impact of Type 2 Diabetes Mellitus on Long-Term Prognosis in Patients of Different Ages with Myocardial Infarction”
por: Afanasiev, S. A., et al.
Publicado: (2019)

Anticoagulation in type 2 myocardial infarctions: Lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial
por: Gouda, Pishoy, et al.
Publicado: (2023)

Low levels of the innate immune system proteins MASP‐2 and MAp44 in patients with common variable immunodeficiency
por: Mistegaard, Clara Elbæk, et al.
Publicado: (2022)

Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
por: Kerola, Anne M., et al.
Publicado: (2022)

Increased Risk of Myocardial Infarction in Depressed Patients With Type 2 Diabetes
por: Scherrer, Jeffrey F., et al.
Publicado: (2011)

ST-Segment Elevation Myocardial Infarction in Women With Type 2 Diabetes
por: Radomska, Edyta, et al.
Publicado: (2013)

Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective
por: Cui, Jing, et al.
Publicado: (2021)

Diet in Patients with Myocardial Infarction and Coexisting Type 2 Diabetes Mellitus
por: Szczepańska, Elżbieta, et al.
Publicado: (2023)

The Course and Prognosis of Myocardial Infarction
Publicado: (1931)

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study
por: Fortin, Elena, et al.
Publicado: (2022)

Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
por: Dørflinger, Gry Høst, et al.
Publicado: (2017)

The role of complement C3 in the outcome of regional myocardial infarction
por: Fang, Zhou, et al.
Publicado: (2023)

Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients
por: Sun, Jia-Yin, et al.
Publicado: (2013)

Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm
por: Sato, Ryota, et al.
Publicado: (2020)

Platelets and the Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus or Antiphospholipid Syndrome
por: Vils, Signe Risbøl, et al.
Publicado: (2023)

Significantly increased levels of serum malonaldehyde in type 2 diabetics with myocardial infarction
por: Mahreen, Rashida, et al.
Publicado: (2010)

Hyperlactatemia and the Outcome of Type 2 Diabetic Patients Suffering Acute Myocardial Infarction
por: Aleksandar, Jovanovic, et al.
Publicado: (2016)

Regulation of Type 2 Immunity in Myocardial Infarction
por: Xu, Jun-Yan, et al.
Publicado: (2019)

Ficolin B in Diabetic Kidney Disease in a Mouse Model of Type 1 Diabetes
por: Holt, Charlotte Berg, et al.
Publicado: (2015)

Sudden Cardiac Death After Myocardial Infarction in Type 2 Diabetic Patients With No Residual Myocardial Ischemia
por: Yeung, Chun-Yip, et al.
Publicado: (2012)

Clinical Frailty Scale classes are independently associated with 6-month mortality for patients after acute myocardial infarction
por: Ekerstad, Niklas, et al.
Publicado: (2021)

The clinical features and prognosis of type 4C myocardial infarction in patients with non-ST-segment elevation myocardial infarction
por: Wang, Jixiang, et al.
Publicado: (2021)

Possible role of complement factors and their inhibitors in the myocardial infarction: an immunohistochemical study
por: Ilczuk, Tomasz, et al.
Publicado: (2014)

The Role of Complement in Myocardial Infarction Reperfusion Injury: An Underappreciated Therapeutic Target
por: Vogel, Carl-Wilhelm
Publicado: (2020)

Diabetes Is Associated with Increased Autoreactivity of Mannan-Binding Lectin
por: Axelgaard, Esben, et al.
Publicado: (2017)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
por: Evans, Lyndon Marc, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g3n39nlg7n933supco1mdd5ptc